The U.S. Securities and Exchange Commission (SEC) declared today that the registration statement (form of prospectus) filed by Alvotech on August 21, 2024 has now taken effect.

On Tuesday August 27, 2024, Alvotech filed a letter with the U.S. Securities and Exchange Commission (SEC), pertaining to its August 21, 2024, filing of a preliminary prospectus, or “registration statement”. In this letter, Alvotech requests that the SEC takes appropriate actions for the registratio

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 22nd...

On Wednesday August 21, 2024, Alvotech filed a preliminary prospectus on form F-3 with the U.S. Securities and Exchange Commission (SEC). Alvotech filed this preliminary prospectus with the SEC to fulfill contractual obligations with an existing shareholder, Morgan Stanley & Co. (the „shareholder“).

Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190%...

The approvals process is anticipated to be completed in the third quarter of 2025 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the...

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously...